GlaxoSmithKline has provided updated information concerning new safety information about type 2 diabetes therapies containing rosiglitazone (Avandia, Avandamet).

The company received very rare postmarketing reports of new-onset and worsening diabetic macular edema for patients receiving rosiglitazone. In the majority of these cases, the patients also reported concurrent peripheral edema. In some cases, the macular edema resolved or improved after the therapy was discontinued and in one case, macular edema resolved after dose reduction.